Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
21.45
-0.20 (-0.92%)
At close: Jul 18, 2025, 4:00 PM
21.59
+0.14 (0.65%)
After-hours: Jul 18, 2025, 7:57 PM EDT
Schrödinger Revenue
Schrödinger had revenue of $59.55M in the quarter ending March 31, 2025, with 62.72% growth. This brings the company's revenue in the last twelve months to $230.49M, up 22.29% year-over-year. In the year 2024, Schrödinger had annual revenue of $207.54M, down -4.21%.
Revenue (ttm)
$230.49M
Revenue Growth
+22.29%
P/S Ratio
6.78
Revenue / Employee
$258,689
Employees
891
Market Cap
1.57B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SDGR News
- 1 day ago - Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration - GlobeNewsWire
- 1 day ago - Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target - Business Wire
- 22 days ago - Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia - Business Wire
- 5 weeks ago - Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
- 5 weeks ago - Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress - Business Wire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation - Accesswire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect - Accesswire